Presentation is loading. Please wait.

Presentation is loading. Please wait.

P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis  Hossein Borghaei, Julie Brahmer,

Published byNoëlle Bruneau Modified over 5 years ago

Similar presentations

Presentation on theme: "P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis  Hossein Borghaei, Julie Brahmer,"— Presentation transcript:

1 P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis  Hossein Borghaei, Julie Brahmer, Leora Horn, Neal Ready, Martin Steins, Enriqueta Felip, Luis Paz-Ares, Xx Xx, Fabrice Barlesi, Scott Antonia, Jérome Fayette, Naiyer Rizvi, Lucio Crino, Martin Reck, Wilfried Ernst Erich Eberhardt, Matthew Hellmann, Kaushal Desai, Ang Li, Diane Healey, David Spigel, Clarissa Mathias  Journal of Thoracic Oncology  Volume 11, Issue 10, Pages S237-S238 (October 2016) DOI: /j.jtho Copyright © Terms and Conditions

2 Journal of Thoracic Oncology 2016 11, S237-S238DOI: (10. 1016/j. jtho
Copyright © Terms and Conditions

Download ppt "P2.35: Nivolumab vs Docetaxel in Advanced NSCLC: CheckMate 017/057 2-Y Update and Exploratory Cytokine Profile Analysis  Hossein Borghaei, Julie Brahmer,"

Similar presentations

Julie Brahmer, M. D. , Karen L. Reckamp, M. D. , Paul Baas, M. D

Julie Brahmer, M. D. , Karen L. Reckamp, M. D. , Paul Baas, M. D
SC17.02 Lung Cancer in China: Challenges and Perspectives

SC17.02 Lung Cancer in China: Challenges and Perspectives
Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)

Journal of Thoracic Oncology  Volume 11, Issue 4, Pages (April 2016)
MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial 

MA09.05 Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial 
PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)  Gilberto De Castro,

PL03.07: First-line Ceritinib Versus Chemotherapy in Patients with ALK-rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND-4)  Gilberto De Castro,
Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD 
Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)

Journal of Thoracic Oncology  Volume 12, Issue 3, Pages (March 2017)
Electronic Updates for JTO Readers

Electronic Updates for JTO Readers
IA05.01 Lung Cancer Cases Journal of Thoracic Oncology

IA05.01 Lung Cancer Cases Journal of Thoracic Oncology
P2.01-082 Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma  Yuqing Lou,

P Transcriptional Profiling Identified the Anti-Proliferative Effect of Mitofusin-2 Deficiency and Its Risk in Lung Adenocarcinoma  Yuqing Lou,
P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.

P3.02c-030 Use of a 200-Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)  Edward Garon, Martin Reck, Delvys.
P1.08-020 The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.

P The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)  Nicholas Faris, Meredith.
P1.05-044 The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort  Matthew Smeltzer,

P The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort  Matthew Smeltzer,
P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig.

P2.33: Safety Profile of Nivolumab Administered as 30-Minute (MIN) Infusion: Analysis of Data From Checkmate 153  David Waterhouse, Leora Horn, Craig.
Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)

Journal of Thoracic Oncology  Volume 12, Issue 5, Pages (May 2017)
Confessions of a journal junkie

Confessions of a journal junkie
Journal of Thoracic Oncology  Volume 13, Issue 2, Pages (February 2018)

Journal of Thoracic Oncology  Volume 13, Issue 2, Pages (February 2018)
P3.06-003 SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,

P SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomized Phase III Trial  Yenting Ngai,
P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153  David Spigel,

P3.02c-026 Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non-Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153  David Spigel,
PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC 

PS01.59: CheckMate 370: A Master Protocol of Phase 1/2 Studies of Nivolumab as Maintenance or First-Line ± Standard-of-Care Therapies in Advanced NSCLC 

Similar presentations

Ads by Google